Add to a list

Inactive Instrument

Acura Pharmaceuticals, Inc. Stock Nasdaq

US00509L7038

Biotechnology & Medical Research

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Valuation: Acura Pharmaceuticals, Inc.

Market Cap	3.28M 2.86M 2.65M 2.48M 4.65M 309M 4.68M 31.41M 12.17M 152M 12.31M 12.04M 529M	P/E 2020	-5.25x	P/E 2021	-25x
Enterprise Value	3.41M 2.98M 2.76M 2.58M 4.84M 322M 4.87M 32.7M 12.67M 159M 12.81M 12.54M 550M	EV / Sales 2020	2.91x	EV / Sales 2021	20.9x
Free-Float	98.31%	Yield 2020 *	-	Yield 2021	-

* Estimated data More valuation ratios

Latest news : Acura Pharmaceuticals, Inc.

03-10	Acura Pharmaceuticals, Inc. Receives Loans of $100,000 from Abuse Deterrent Pharma, LLC	CI
03-09	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
12-11	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
25-09-04	Acura Pharmaceuticals, Inc. Announces Loans from Abuse Deterrent Pharma, LLC	CI
25-09-02	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
25-07-17	Acura Pharmaceuticals, Inc. announced that it has received $8.394279 million in funding from Abuse Deterrent Pharma, LLC	CI
25-06-19	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
25-05-30	Acura Pharmaceuticals, Inc. Announces License, Development and Commercialization Agreement with AD Pharma	CI
25-05-30	Acura Pharmaceuticals, Inc. Amends Amend the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note with AD Pharma	CI
25-05-21	Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Announces Second Meeting with US Food and Drug Administration	CI
25-04-23	Acura Pharmaceuticals, Inc. Receives Loan from Abuse Deterrent Pharma, LLC	CI
25-02-27	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
25-01-22	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI

More news

Press Releases: Acura Pharmaceuticals, Inc.

24-12-16	Acura Pharmaceuticals : Financial Obligation Form 8 K	PU
24-07-26	Acura Pharmaceuticals : New Financial Obligation Form 8 K	PU
24-03-26	Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	PU
23-12-21	Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	PU
23-12-06	Acura Pharmaceuticals : New Financial Obligation - Form 8-K	PU

More press releases

Managers and Directors: Acura Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Jones CEO	Chief Executive Officer	67	2011-03-31
Bob Seiser DFI	Director of Finance/CFO	62	2024-07-31
Albert Brzeczko CTO	Chief Tech/Sci/R&D Officer	69	2009-01-31

Director	Title	Age	Since
Bruce Wesson BRD	Director/Board Member	83	1998-02-28
William Skelly CHM	Chairman	75	1996-09-30
Immanuel Thangaraj BRD	Director/Board Member	55	2002-11-30

More insiders

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Employees

Sector

Biotechnology & Medical Research

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACURA PHARMACEUTICALS, INC.	+7.77%	+5.17%	-	-	26.66K
ARGENX SE	+1.99%	+3.89%	+69.70%	+117.79%	55.19B
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+57.38%	+62.27%	45.75B
BIONTECH SE	+0.04%	+0.44%	-11.46%	-15.01%	22.98B
INSMED INCORPORATED	+2.85%	+1.99%	-5.71%	+388.69%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	-0.26%	-0.58%	+25.47%	-18.57%	16.26B
GENMAB A/S	+0.47%	+3.45%	+21.88%	-36.67%	15.42B
EXELIXIS, INC.	-0.67%	-1.66%	+20.18%	+162.17%	13.05B
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+125.78%	+261.94%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.63%	-6.39%	+19.78%	-	12.37B
Average	+1.67%	+2.28%	+35.89%	+115.33%	23.8B
Weighted average by Cap.	+1.79%	+1.51%	+41.61%	+106.93%

	2020	2021
Net sales	3.57M 3.11M 2.88M 2.7M 5.06M 337M 5.09M 34.2M 13.25M 166M 13.4M 13.11M 576M	1.56M 1.36M 1.26M 1.18M 2.22M 147M 2.23M 14.97M 5.8M 72.59M 5.87M 5.74M 252M
Net income	-1.21M -1.05M -975K -913K -1.71M -114M -1.72M -11.57M -4.48M -56.1M -4.53M -4.44M -195M	-879K -766K -710K -664K -1.25M -82.94M -1.25M -8.42M -3.26M -40.82M -3.3M -3.23M -142M
Net Debt	5.86M 5.11M 4.73M 4.43M 8.3M 553M 8.35M 56.1M 21.74M 272M 21.98M 21.51M 944M	135K 118K 109K 102K 191K 12.74M 193K 1.29M 501K 6.27M 507K 496K 21.77M

Acura Pharmaceuticals, Inc. Stock Nasdaq

Stocks

US00509L7038

Biotechnology & Medical Research

Valuation: Acura Pharmaceuticals, Inc.

Latest news : Acura Pharmaceuticals, Inc.

Press Releases: Acura Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Acura Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile